Élise Fortin1, Caroline Sirois2, Caroline Quach2, Sonia Jean2, Marc Simard2, Marc Dionne2, Alejandra Irace-Cima2, Nadine Magali-Ufitinema2. 1. Institut national de santé publique du Québec (Fortin, Sirois, Jean, Simard, Irace-Cima), Québec, Que.; Department of Microbiology, Infectious Diseases and Immunology (Fortin, Quach), Faculty of Medicine, University of Montreal, Montréal, Que.; Department of Social and Preventive Medicine (Fortin, Sirois, Simard), Faculty of Medicine, Laval University; Centre d'excellence sur le vieillissement de Québec (Sirois), Centre de recherche du CHU de Québec; Department of Medicine (Jean), Faculty of Medicine, Laval University; Centre de recherche du CHU de Québec (Dionne), Québec, Que.; Direction de la prévention et du contrôle des maladies infectieuses (Magali-Ufitinema), Direction générale adjointe de la protection de la santé publique, Ministère de la Santé et des Services sociaux, Montréal, Que. elise.fortin@inspq.qc.ca. 2. Institut national de santé publique du Québec (Fortin, Sirois, Jean, Simard, Irace-Cima), Québec, Que.; Department of Microbiology, Infectious Diseases and Immunology (Fortin, Quach), Faculty of Medicine, University of Montreal, Montréal, Que.; Department of Social and Preventive Medicine (Fortin, Sirois, Simard), Faculty of Medicine, Laval University; Centre d'excellence sur le vieillissement de Québec (Sirois), Centre de recherche du CHU de Québec; Department of Medicine (Jean), Faculty of Medicine, Laval University; Centre de recherche du CHU de Québec (Dionne), Québec, Que.; Direction de la prévention et du contrôle des maladies infectieuses (Magali-Ufitinema), Direction générale adjointe de la protection de la santé publique, Ministère de la Santé et des Services sociaux, Montréal, Que.
Abstract
BACKGROUND: Chronic diseases may increase risk of infection and complications from infections; fear of these risks may lower clinicians' tolerance threshold for the prescription of antimicrobials, thus increasing the risk of selecting resistant bacteria. We sought to describe rates of antimicrobial use in Quebec and measure the association between chronic diseases and utilization rates. METHODS: Using the Quebec Integrated Chronic Disease Surveillance System, we analyzed data of people covered by the public drug insurance plan in 2002-2017. Based on delivered prescriptions, we described trends in antimicrobial use in the population, and per category of select chronic diseases (i.e., none, respiratory, cardiovascular, diabetes, mental disorder), according to age group (0-17 yr, 18-64 yr and ≥ 65 yr). We computed ratios of extended-to-narrow-spectrum antimicrobials in 2014-2017. We used robust Poisson regression to quantify the association between chronic diseases and rates of antimicrobial use among children and adults (≥ 18 yr). RESULTS: Between 2002 and 2017, 4 231 724 prescriptions were received over 6 653 473 individual-years among children; 1 367 492 (20.6%) individual-years had at least 1 chronic disease. Among adults aged 18-64 years, 13 365 577 prescriptions were received over 24 935 592 individual-years; 9 533 493 (38.2%) individual-years had at least 1 chronic disease. Among adults 65 years or older, 11 689 365 prescriptions were received over 15 927 342 individual-years; 12 743 588 (80.0%) individual-years had least 1 chronic disease. Antimicrobial use decreased among children, remained stable among younger adults and increased among older adults. Trends were consistent across chronic disease categories in children and older adults. In 2014-2017, 19.9% of children, 39.1% of younger adults and 79.7% of older adults had at least 1 chronic disease. Claims for extended-spectrum antimicrobials were frequent in all age and chronic disease groups, relative to narrow-spectrum antimicrobials (ratios from 3.1:1 to 14.6:1). Antimicrobial use was higher among people with respiratory diseases (adults: relative rate [RR] 2.09, 95% confidence interval [CI] 2.07-2.10; children: RR 1.62, 95% CI 1.59-1.65), mental health diagnoses (adults: RR 1.48, 95% CI 1.46-1.49; children: RR 1.22, 95% 1.20-1.24), diabetes (adults: RR 1.40, 95% CI 1.28-1.41; children: RR 2.02, 95% CI 1.58-2.57) and cardiovascular diseases (adults: RR 1.31, 95% CI 1.30-1.32), compared with those with none of the studied chronic diseases. INTERPRETATION: During the study period, large proportions of antimicrobial prescriptions were for people with chronic diseases, across the age spectrum. Interventions to reduce antimicrobial use should be tailored for these populations.
BACKGROUND: Chronic diseases may increase risk of infection and complications from infections; fear of these risks may lower clinicians' tolerance threshold for the prescription of antimicrobials, thus increasing the risk of selecting resistant bacteria. We sought to describe rates of antimicrobial use in Quebec and measure the association between chronic diseases and utilization rates. METHODS: Using the Quebec Integrated Chronic Disease Surveillance System, we analyzed data of people covered by the public drug insurance plan in 2002-2017. Based on delivered prescriptions, we described trends in antimicrobial use in the population, and per category of select chronic diseases (i.e., none, respiratory, cardiovascular, diabetes, mental disorder), according to age group (0-17 yr, 18-64 yr and ≥ 65 yr). We computed ratios of extended-to-narrow-spectrum antimicrobials in 2014-2017. We used robust Poisson regression to quantify the association between chronic diseases and rates of antimicrobial use among children and adults (≥ 18 yr). RESULTS: Between 2002 and 2017, 4 231 724 prescriptions were received over 6 653 473 individual-years among children; 1 367 492 (20.6%) individual-years had at least 1 chronic disease. Among adults aged 18-64 years, 13 365 577 prescriptions were received over 24 935 592 individual-years; 9 533 493 (38.2%) individual-years had at least 1 chronic disease. Among adults 65 years or older, 11 689 365 prescriptions were received over 15 927 342 individual-years; 12 743 588 (80.0%) individual-years had least 1 chronic disease. Antimicrobial use decreased among children, remained stable among younger adults and increased among older adults. Trends were consistent across chronic disease categories in children and older adults. In 2014-2017, 19.9% of children, 39.1% of younger adults and 79.7% of older adults had at least 1 chronic disease. Claims for extended-spectrum antimicrobials were frequent in all age and chronic disease groups, relative to narrow-spectrum antimicrobials (ratios from 3.1:1 to 14.6:1). Antimicrobial use was higher among people with respiratory diseases (adults: relative rate [RR] 2.09, 95% confidence interval [CI] 2.07-2.10; children: RR 1.62, 95% CI 1.59-1.65), mental health diagnoses (adults: RR 1.48, 95% CI 1.46-1.49; children: RR 1.22, 95% 1.20-1.24), diabetes (adults: RR 1.40, 95% CI 1.28-1.41; children: RR 2.02, 95% CI 1.58-2.57) and cardiovascular diseases (adults: RR 1.31, 95% CI 1.30-1.32), compared with those with none of the studied chronic diseases. INTERPRETATION: During the study period, large proportions of antimicrobial prescriptions were for people with chronic diseases, across the age spectrum. Interventions to reduce antimicrobial use should be tailored for these populations.
Authors: Élise Fortin; Sonia Jean; Caroline Sirois; Marc Simard; Alejandra Irace-Cima; Valérie Émond; Marc Dionne Journal: Can J Public Health Date: 2020-01-14
Authors: Laura Shallcross; Nick Beckley; Greta Rait; Andrew Hayward; Irene Petersen Journal: J Antimicrob Chemother Date: 2017-06-01 Impact factor: 5.790
Authors: Esmé J Baan; Hettie M Janssens; Tine Kerckaert; Patrick J E Bindels; Johan C de Jongste; Miriam C J M Sturkenboom; Katia M C Verhamme Journal: BMJ Open Date: 2018-11-28 Impact factor: 2.692
Authors: Yuanyuan Wang; Muh Akbar Bahar; Anouk M E Jansen; Janwillem W H Kocks; Jan-Willem C Alffenaar; Eelko Hak; Bob Wilffert; Sander D Borgsteede Journal: J Antimicrob Chemother Date: 2019-10-01 Impact factor: 5.790
Authors: Eric I Benchimol; Liam Smeeth; Astrid Guttmann; Katie Harron; David Moher; Irene Petersen; Henrik T Sørensen; Erik von Elm; Sinéad M Langan Journal: PLoS Med Date: 2015-10-06 Impact factor: 11.069
Authors: Salud Santos; Alicia Marin; Joan Serra-Batlles; David de la Rosa; Ingrid Solanes; Xavier Pomares; Marta López-Sánchez; Mariana Muñoz-Esquerre; Marc Miravitlles Journal: Int J Chron Obstruct Pulmon Dis Date: 2016-03-11